Printer Friendly

ONCOR REPORTS RECORD SALES FOR FOURTH QUARTER AND FULL YEAR 1992

 GAITHERSBURG, Md., March 3 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR) reported financial results for the fourth quarter and year ended Dec. 31, 1992.
 Consolidated net product sales in the fourth quarter of 1992 increased by 58 percent to a record $1.9 million, compared with $1.2 million in the fourth quarter of 1991. The company recorded a consolidated net loss of $2.9 million or $0.19 per share in the fourth quarter of 1992, compared with a net loss of $1.7 million or $0.16 per share in the same period of 1991.
 Consolidated net product sales for the year ended Dec. 31, 1992 increased by 38 percent to $6.5 million, compared with $4.7 million in 1991. Total consolidated revenues, which included $1.1 million in contract revenues for the year of 1991 and $100,000 of grant revenue for the year of 1992, increased from $5.7 million in 1991 to $6.6 million in 1992.
 Oncor reported a net operating loss in 1992 of $7.8 million or $0.54 per share, before a one-time net charge of $1.5 million incurred in order to terminate royalty payments required under a research and development contract. Including this one-time charge, the company reported a net loss of $9.2 million or $0.64 per share in 1992. This compares with a net loss of $4.2 million or $0.42 per share for the year of 1991.
 As of Dec. 31, 1992, the company had cash, cash equivalents and short-term investments of $27.9 million.
 The financial results for both the fourth quarter and full year 1992 have been restated and consolidated to reflect the Company's combination with American Innovision, Inc. (a California corporation) in a pooling of interests in November 1992.
 Stephen Turner, chairman and chief executive officer, said, "We are pleased with the sustained increases in Oncor's product sales, which reflect the growing demand for gene-based medical diagnostics. The operating loss for the year was due primarily to a substantial increase of Oncor's R&D investment, as well as the completion of a number of external research and gene-licensing agreements, most notably with The Johns Hopkins University School of Medicine. We also increased our selling, general and administrative expenses primarily to expand our field sales force and increase our marketing activities."
 "Looking ahead, we are optimistic about our future prospects. We expect a substantial increase in product sales this year. Oncor currently has 22 clinical studies underway to obtain FDA approvals for DNA probes to detect lung, bladder, breast, and prostate cancers over the next two to three years," Mr. Turner concluded.
 Oncor develops, manufactures and markets Human Genome-based test systems for use in the early detection and management of cancer and other genetic diseases.
 ONCOR, INC.
 Consolidated Statements of Operations
 (unaudited)
 Periods ended
 Dec. 31 Three Months Ended Year Ended
 1992 1991 1992 1991
 Gross Revenues:
 Product $1,879,307 $1,058,735 $6,480,157 $4,687,488
 Contract - - 99,649 1,050,000
 Gross Revenues 1,879,307 1,058,735 6,579,806 5,737,488
 Operating expenses:
 Direct cost of
 sales 946,198 676,812 3,555,147 2,849,668
 Selling, general and
 administrative 1,883,525 1,420,282 5,912,658 4,193,088
 Research and
 development 2,174,002 951,097 5,951,740 2,976,348
 Total operating
 expenses 5,003,725 3,048,191 15,419,545 10,019,104
 Loss from
 operations (3,124,418) (1,989,456) (8,839,739) (4,281,616)
 Other income (expense):
 Investment income -- -- 1,114,236 162,004
 Other income
 (expense) 240,605 52,989 (62,778) (59,814)
 Total other income
 (expense) 240,605 52,989 1,051,458 102,190
 Net operating loss:
 (before buyout of Hickley
 research and development
 contract) -- -- (7,788,281) (4,179,426)
 Buyout of research and
 development
 contract -- -- 1,446,820 --
 Net loss ($2,883,813) ($1,936,467) ($9,235,101) ($4,179,426)
 Net loss per
 share ($0.19) ($0.18) ($0.64) ($0.42)
 Weighted average common
 outstanding 15,078,969 11,049,161 14,518,291 9,862,752
 -0- 3/3/93
 /CONTACT: Robert Borchert of Morgen-Walke Associates, 212-986-5900, for Oncor, Inc./
 (ONCR)


CO: Oncor, Inc. ST: Maryland IN: MTC SU: ERN

TM -- NY003 -- 2268 03/03/93 08:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1993
Words:728
Previous Article:DAY RUNNER(R) APPOINTS CHIEF OPERATING OFFICER
Next Article:VENTURE STORES, INC. REPORTS FISCAL 1992 EARNINGS PER SHARE BEFORE EXTRAORDINARY ITEM OF $2.82 AND FEBRUARY 1993 SALES RESULTS
Topics:


Related Articles
ONCOR REPORTS RECORD NET PRODUCT SALES IN SECOND QUARTER ENDED JUNE 30, 1992
ONCOR AND UNIVERSITY OF UTAH TO DEVELOP GENETIC TESTS FOR PROSTATE CANCER
ONCOR, INC. REPORTS RECORD PRODUCT SALES OF $1.5 MILLION IN THE THIRD QUARTER, 1992
ZOOM TELEPHONICS REPORTS RECORD SALES
ONCOR REPORTS RECORD SALES FOR FIRST QUARTER 1993
ONCOR REPORTS RECORD SALES FOR SECOND QUARTER AND SIX MONTHS OF 1993
ONCOR, INC. REPORTS OPERATING RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 1993
ONCOR, INC. REPORTS RECORD SALES FOR FOURTH QUARTER AND FULL YEAR 1993
ONCOR INC. REPORTS FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 1994
ONCOR INC. REPORTS RESULTS FOR YEAR AND QUARTER ENDED DECEMBER 31, 1995

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters